Apria - resources

resources

	Community
	Health Advisors
	Patient Education
	Other Sources
	Glossaries
	Product Manuals
	FAQS
	News
	Electronic CMN

	Search Apria articles:

Channels

	Cancer
	Caregivers
	Degenerative Conditions
	Diabetes
	Heart
	Infectious Diseases
	Pediatrics
	Respiratory
	Seniors
	Sleep Disorders

ZIOP: FDA Grants Orphan Drug Designation to Palifosfamide

Ridgeland, MS, MAY 09, 2008 (EventX/Knobias.com via COMTEX) -- By Fain Hughes, fhughes@knobias.com

ZIOPHARM Oncology, Inc. (ZIOP) announced that the FDA has granted Orphan Drug Designation to palifosfamide in the treatment of Soft Tissue Sarcoma (STS). The Orphan Drug designation provides eligibility for a seven-year period of market exclusivity in the United States after product approval, an accelerated review process, grant funding, tax benefits and an exemption from user fees.

Soft tissue sarcomas can occur anywhere within the body including muscle, fat, nerves, vascular tissue, and other connective tissues. STS tumors account for about 1% of all cancers in adults and 10% in children.

KNOBIAS DISCLAIMER: All statements made in this article were made by the Company and do not in any way reflect the opinions of Knobias. Knobias is not a registered broker-dealer, nor investment advisor, and does not endorse or recommend any securities mentioned. This story is provided for informational purposes only and is not intended for trading purposes. Knobias shall not be liable for any actions taken in reliance of any information provided herein. Republication or redistribution of Knobias content is expressly prohibited without prior written consent of Knobias.com, LLC.

ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.

If your company wishes to participate in the EventX newswire, please contact Knobias: http://www.knobias.com

CONTACT: Knobias.com, LLC

601-978-3399

601-978-3675

info@knobias.com

www.knobias.com/cmtx

SUBJECT CODE: FDA/R&D

Watch Stories

KNO-Zone

EventX Service

Important Co. News

PREMARKET

3. Answers

Q:	Why is handwashing so important with IV therapy?

A: Any time anything such as an intravenous catheter penetrates the skin, there is a break in the skin's protective system, and therefore the possibility exists of that area, another affected area or blood becoming infected.

Organisms that ordinarily live on the skin can become harmful if they enter the body. Most infection is spread by hand contact; hands and fingers carry the most organisms. Because your IV catheter and IV site need to remain as clean as possible, everything touching them must be sterile. This is why you must wash your hands before you put on gloves to change your dressing or perform other care of your IV site.

It's equally important to wash your hands thoroughly afterward so that you do not spread any potential infection to other people or other parts of your body.

2008 Apria Healthcare All Rights Reserved.
No duplication of any material herein is authorized without the express consent of Apria Healthcare, Inc.
Please review the Terms and Conditions of this Web site.